JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 71 filers reported holding JOUNCE THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $37,766 | -56.3% | 20,414 | -73.8% | 0.00% | – |
| Q4 2022 | $86,356 | -95.6% | 77,798 | -90.8% | 0.00% | – |
| Q3 2022 | $1,977,000 | -48.4% | 844,787 | -33.3% | 0.00% | – |
| Q2 2022 | $3,835,000 | +428.2% | 1,265,811 | +1083.4% | 0.00% | – |
| Q1 2022 | $726,000 | -74.8% | 106,964 | -69.1% | 0.00% | – |
| Q4 2021 | $2,886,000 | -50.9% | 345,631 | -56.3% | 0.00% | – |
| Q3 2021 | $5,877,000 | +9.3% | 790,934 | 0.0% | 0.00% | – |
| Q2 2021 | $5,378,000 | -29.3% | 790,934 | +6.7% | 0.00% | -100.0% |
| Q1 2021 | $7,610,000 | +823.5% | 741,034 | +529.2% | 0.00% | – |
| Q4 2020 | $824,000 | -38.0% | 117,774 | -27.7% | 0.00% | – |
| Q3 2020 | $1,329,000 | -65.8% | 162,874 | -71.1% | 0.00% | – |
| Q2 2020 | $3,891,000 | +45.2% | 563,974 | 0.0% | 0.00% | – |
| Q1 2020 | $2,679,000 | -75.2% | 563,974 | -54.5% | 0.00% | -100.0% |
| Q4 2019 | $10,814,000 | +340.0% | 1,238,774 | +67.8% | 0.00% | – |
| Q3 2019 | $2,458,000 | -46.0% | 738,174 | -19.7% | 0.00% | -100.0% |
| Q2 2019 | $4,552,000 | -27.1% | 919,577 | -8.7% | 0.00% | 0.0% |
| Q1 2019 | $6,243,000 | +83.9% | 1,006,874 | -0.0% | 0.00% | – |
| Q4 2018 | $3,394,000 | -76.3% | 1,007,115 | -54.3% | 0.00% | -100.0% |
| Q3 2018 | $14,329,000 | -36.4% | 2,204,447 | -25.1% | 0.00% | -33.3% |
| Q2 2018 | $22,538,000 | -66.1% | 2,942,332 | -1.0% | 0.00% | -62.5% |
| Q1 2018 | $66,432,000 | +98.2% | 2,972,332 | +13.1% | 0.01% | +100.0% |
| Q4 2017 | $33,512,000 | -34.3% | 2,628,390 | -19.7% | 0.00% | -33.3% |
| Q3 2017 | $50,984,000 | -4.9% | 3,272,426 | -17.6% | 0.01% | -14.3% |
| Q2 2017 | $53,624,000 | -34.9% | 3,972,016 | -1.8% | 0.01% | -30.0% |
| Q1 2017 | $82,387,000 | – | 4,046,316 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 2,697,829 | $22,527,000 | 93.16% |
| TRV GP III, LLC | 1,148,780 | $9,592,000 | 2.40% |
| Deep Track Capital, LP | 4,000,000 | $33,400,000 | 2.36% |
| Ally Bridge Group (NY) LLC | 575,000 | $4,801,000 | 1.68% |
| Logos Global Management LP | 1,350,000 | $11,273,000 | 1.16% |
| PFM Health Sciences, LP | 3,972,868 | $33,173,000 | 1.13% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 245,829 | $2,053,000 | 0.83% |
| Yorktown Management & Research Co Inc | 137,300 | $1,146,000 | 0.77% |
| Sofinnova Investments, Inc. | 1,582,777 | $13,216,000 | 0.77% |
| ACUTA CAPITAL PARTNERS, LLC | 127,500 | $1,065,000 | 0.45% |